EPRS 4.57 Epirus Biopharmaceuticals Inc. $EPRS Hit
Post# of 87
Posted On: 11/10/2014 10:36:14 PM
EPRS 4.57 Epirus Biopharmaceuticals Inc. $EPRS Hit a 52 week low of 4.43 Closing the day 11/10/14 at 4.57 +0.06 +1.33% With a day low of 4.43 and a total volume of 24,847.
EPRS Recent Posts: http://investorshangout.com/EPIRUS-Biopharmac...PRS-55967/
EPRS Epirus Biopharmaceuticals Inc. Recent Headline News
EPIRUS Biopharmaceuticals EPS of -$1.28
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 4:17PM CST
EPRS: 4.57 (+0.06)
EPIRUS Biopharmaceuticals Reports Third Quarter Results and Provides Corporate Update
Business Wire - Mon Nov 10, 3:30PM CST
EPIRUS Biopharmaceuticals, Inc. (EPIRUS, NASDAQ:EPRS), a Boston-based biopharmaceutical company focused on the global development and commercialization of biosimilar monoclonal antibodies, today provided a corporate update and reported financial results for the third quarter ended September 30, 2014.
ZLCS: 1.18 (+0.03), EPRS: 4.57 (+0.06)
EPIRUS and Livzon Mabpharm, Inc. Enter Collaboration Agreement for China
Business Wire - Thu Sep 25, 7:00AM CDT
EPIRUS Biopharmaceuticals, Inc. (EPIRUS, NASDAQ: EPRS), a Boston-based biopharmaceutical company focused on the global development and commercialization of biosimilar monoclonal antibodies, announced today that it has signed a royalty-bearing, multi-product collaboration agreement with Livzon Mabpharm Inc. (Livzon), a Chinese biotechnology company focused on the development, manufacture, and sale of antibody-based drugs. Livzon was also a principal investor in the $36 million private financing round EPIRUS closed in April 2014, prior to becoming a public company.
EPRS: 4.57 (+0.06)
EPIRUS Announces Positive 58 Week Follow up Data for BOW015 for Treatment of Rheumatoid Arthritis
Business Wire - Tue Sep 23, 7:00AM CDT
EPIRUS Biopharmaceuticals, Inc. (EPIRUS, NASDAQ:EPRS), a Boston-based biopharmaceutical company focused on the global development and commercialization of biosimilar monoclonal antibodies, today announced positive 58 week follow up data from its BOW015 efficacy and safety trial comparing BOW015, a biosimilar infliximab, to Remicade.
EPRS: 4.57 (+0.06)
EPIRUS to Present at NewsMakers in the Biotech Industry Conference
Business Wire - Mon Sep 22, 7:00AM CDT
EPIRUS Biopharmaceuticals, Inc. (EPIRUS, NASDAQ: EPRS), a Boston-based biopharmaceutical company focused on the global development and commercialization of biosimilar monoclonal antibodies, today announced that the company will present at the NewsMakers in the Biotech Industry conference at 2:30 PM EDT, Friday, September 26, at the Millennium Broadway Hotel in New York City. Amit Munshi, President and CEO of EPIRUS, will present the company's recent developments, including the approval in India of BOW015; business model; and pipeline.
EPRS: 4.57 (+0.06)
EPIRUS' Remicade(R) Biosimilar Receives Final Approvals in India
Business Wire - Mon Sep 15, 3:00PM CDT
EPIRUS Biopharmaceuticals, Inc. (EPIRUS, NASDAQ:EPRS), a Boston-based biopharmaceutical company focused on the global development and commercialization of biosimilar monoclonal antibodies, announced today that it has received final marketing and manufacturing approvals for its Remicade(R) (infliximab) biosimilar, BOW015, from the Drug Controller General of India (DCGI). BOW015 is the first infliximab biosimilar approved in India.
EPRS: 4.57 (+0.06)
EPIRUS to Present at Wedbush Life Sciences Management Access Conference
Business Wire - Thu Aug 07, 3:58PM CDT
EPIRUS Biopharmaceuticals, Inc. (EPIRUS, NASDAQ:EPRS), a Boston-based biopharmaceutical company focused on the global development and commercialization of biosimilar monoclonal antibodies, today announced that the company will present at the Wedbush Life Sciences Management Access Conference at 4:15 p.m. EDT, Tuesday, Aug. 12, at the Le Parker Meridien in New York City. The presentation will include discussion of the company's recent developments, business model and pipeline.
EPRS: 4.57 (+0.06)
Mark H.N. Corrigan, M.D., Julie H. McHugh, and William Hunter, M.D. to Serve on EPIRUS Board of Directors
Business Wire - Tue Jul 15, 10:49AM CDT
EPIRUS Biopharmaceuticals, Inc. (EPIRUS, NASDAQ: EPRS), a Boston-based biopharmaceutical company focused on the global development and commercialization of biosimilar monoclonal antibodies, announced that Mark H.N. Corrigan, M.D., Julie H. McHugh, and William Hunter, M.D. will serve on its board of directors. The board, which was reconstituted today following the company's merger with Zalicus Inc. (Zalicus, NASDAQ: ZLCS), also includes Amit Munshi, Geoffrey Duyk, Scott Rocklage, J. Kevin Buchi and Daotian Fu.
CRME: 8.54 (+0.49), TRVN: 5.85 (-0.06), AVNR: 13.22 (+0.20), ZLCS: 1.18 (+0.03), IRWD: 13.84 (unch), CBST: 71.48 (+1.10), EPRS: 4.57 (+0.06)
EPIRUS and Zalicus Complete Merger - Combined Company Will Trade as EPIRUS Biopharmaceuticals, Inc. (NASDAQ: EPRS)
Business Wire - Tue Jul 15, 10:47AM CDT
--EPIRUS reconstitutes Board of Directors to include Mark H.N. Corrigan, M.D., Julie H. McHugh, William Hunter, M.D., Amit Munshi, Geoffrey Duyk, Scott Rocklage, J. Kevin Buchi and Daotian Fu
ZLCS: 1.18 (+0.03), EPRS: 4.57 (+0.06)
EPRS Recent Posts: http://investorshangout.com/EPIRUS-Biopharmac...PRS-55967/
EPRS Epirus Biopharmaceuticals Inc. Recent Headline News
EPIRUS Biopharmaceuticals EPS of -$1.28
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 4:17PM CST
EPRS: 4.57 (+0.06)
EPIRUS Biopharmaceuticals Reports Third Quarter Results and Provides Corporate Update
Business Wire - Mon Nov 10, 3:30PM CST
EPIRUS Biopharmaceuticals, Inc. (EPIRUS, NASDAQ:EPRS), a Boston-based biopharmaceutical company focused on the global development and commercialization of biosimilar monoclonal antibodies, today provided a corporate update and reported financial results for the third quarter ended September 30, 2014.
ZLCS: 1.18 (+0.03), EPRS: 4.57 (+0.06)
EPIRUS and Livzon Mabpharm, Inc. Enter Collaboration Agreement for China
Business Wire - Thu Sep 25, 7:00AM CDT
EPIRUS Biopharmaceuticals, Inc. (EPIRUS, NASDAQ: EPRS), a Boston-based biopharmaceutical company focused on the global development and commercialization of biosimilar monoclonal antibodies, announced today that it has signed a royalty-bearing, multi-product collaboration agreement with Livzon Mabpharm Inc. (Livzon), a Chinese biotechnology company focused on the development, manufacture, and sale of antibody-based drugs. Livzon was also a principal investor in the $36 million private financing round EPIRUS closed in April 2014, prior to becoming a public company.
EPRS: 4.57 (+0.06)
EPIRUS Announces Positive 58 Week Follow up Data for BOW015 for Treatment of Rheumatoid Arthritis
Business Wire - Tue Sep 23, 7:00AM CDT
EPIRUS Biopharmaceuticals, Inc. (EPIRUS, NASDAQ:EPRS), a Boston-based biopharmaceutical company focused on the global development and commercialization of biosimilar monoclonal antibodies, today announced positive 58 week follow up data from its BOW015 efficacy and safety trial comparing BOW015, a biosimilar infliximab, to Remicade.
EPRS: 4.57 (+0.06)
EPIRUS to Present at NewsMakers in the Biotech Industry Conference
Business Wire - Mon Sep 22, 7:00AM CDT
EPIRUS Biopharmaceuticals, Inc. (EPIRUS, NASDAQ: EPRS), a Boston-based biopharmaceutical company focused on the global development and commercialization of biosimilar monoclonal antibodies, today announced that the company will present at the NewsMakers in the Biotech Industry conference at 2:30 PM EDT, Friday, September 26, at the Millennium Broadway Hotel in New York City. Amit Munshi, President and CEO of EPIRUS, will present the company's recent developments, including the approval in India of BOW015; business model; and pipeline.
EPRS: 4.57 (+0.06)
EPIRUS' Remicade(R) Biosimilar Receives Final Approvals in India
Business Wire - Mon Sep 15, 3:00PM CDT
EPIRUS Biopharmaceuticals, Inc. (EPIRUS, NASDAQ:EPRS), a Boston-based biopharmaceutical company focused on the global development and commercialization of biosimilar monoclonal antibodies, announced today that it has received final marketing and manufacturing approvals for its Remicade(R) (infliximab) biosimilar, BOW015, from the Drug Controller General of India (DCGI). BOW015 is the first infliximab biosimilar approved in India.
EPRS: 4.57 (+0.06)
EPIRUS to Present at Wedbush Life Sciences Management Access Conference
Business Wire - Thu Aug 07, 3:58PM CDT
EPIRUS Biopharmaceuticals, Inc. (EPIRUS, NASDAQ:EPRS), a Boston-based biopharmaceutical company focused on the global development and commercialization of biosimilar monoclonal antibodies, today announced that the company will present at the Wedbush Life Sciences Management Access Conference at 4:15 p.m. EDT, Tuesday, Aug. 12, at the Le Parker Meridien in New York City. The presentation will include discussion of the company's recent developments, business model and pipeline.
EPRS: 4.57 (+0.06)
Mark H.N. Corrigan, M.D., Julie H. McHugh, and William Hunter, M.D. to Serve on EPIRUS Board of Directors
Business Wire - Tue Jul 15, 10:49AM CDT
EPIRUS Biopharmaceuticals, Inc. (EPIRUS, NASDAQ: EPRS), a Boston-based biopharmaceutical company focused on the global development and commercialization of biosimilar monoclonal antibodies, announced that Mark H.N. Corrigan, M.D., Julie H. McHugh, and William Hunter, M.D. will serve on its board of directors. The board, which was reconstituted today following the company's merger with Zalicus Inc. (Zalicus, NASDAQ: ZLCS), also includes Amit Munshi, Geoffrey Duyk, Scott Rocklage, J. Kevin Buchi and Daotian Fu.
CRME: 8.54 (+0.49), TRVN: 5.85 (-0.06), AVNR: 13.22 (+0.20), ZLCS: 1.18 (+0.03), IRWD: 13.84 (unch), CBST: 71.48 (+1.10), EPRS: 4.57 (+0.06)
EPIRUS and Zalicus Complete Merger - Combined Company Will Trade as EPIRUS Biopharmaceuticals, Inc. (NASDAQ: EPRS)
Business Wire - Tue Jul 15, 10:47AM CDT
--EPIRUS reconstitutes Board of Directors to include Mark H.N. Corrigan, M.D., Julie H. McHugh, William Hunter, M.D., Amit Munshi, Geoffrey Duyk, Scott Rocklage, J. Kevin Buchi and Daotian Fu
ZLCS: 1.18 (+0.03), EPRS: 4.57 (+0.06)
(0)
(0)